TOKYO, October 19, 2020 - EPS International Holdings Co., Ltd., the CRO (Clinical Research Organization) with strength in Asia-Pacific clinical trials support, today announced the new President and the Executive Leadership Team.
|Name||New Responsibilities||Previous Responsibilities|
|Tomohisa Hayakawa||President and Representative Director
President and Representative Corporate Officer
Managing Corporate Officer
Head of Business Platform Center
Head of North-East Asia Business Unit
Board of Directors
*EPS International is a company of EPS group
About EPS International and EPS group
Since its establishment in 1991 as one of pioneering CROs, EPS Group has been a Healthcare Solution Provider to pharmaceutical companies, medical device manufacturers, hospitals and clinics, and academia with various solutions from development to marketing, sales, consultation covering Asia centered in China and new values created in big data & AI, regenerative medicine, etc. The strength of EPS International lies in the fact that it has the greatest presence in Japan. In Asia, the company has multiple overseas offices and has focused particularly on solidifying its sites in the respective Asian countries, providing clinical development support services as well as SMO services.
EPS International Holdings Co., Ltd.
7F Kagurazaka AK Bldg.
1-8 Tsukudocho, Shinjuku-ku
Tokyo 162-0821 Japan
EPS International https://www.epsi-global.com/index.html,
EPS Holdings https://www.eps-holdings.co.jp/en/
[For inquiries related to this news release]